Rajasthan Plans End To India Policy Dependence For Open Market
This article was originally published in PharmAsia News
The head of Rajasthan Drugs and Pharmaceuticals says the company has benefited greatly by India's 2006 policy to cover 102 drugs made by central public-sector undertakings. Managing Director R.K. Vashishtha said Rajasthan's gain also was shared by other COSUs, which were given five years of automatic coverage by the government, public sector enterprises and non-government organizations. For Rajasthan, that has led to a large numbers of orders for its drugs, and the company now seeks to enter the open market with its products, eventually becoming self-reliant. (Click here for more
You may also be interested in...
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.